Synapse - Robert Motzer

Results (1247)

A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma

Meeting Abstract

Oya, M.; Tamada, S.; Tatsugami, K.; Nakaigawa, N.; Osawa, T.; Kanayama, H. O.; Kondoh, C.; Sassa, N.; Nishimura, K.; Nozawa, M.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC)

Meeting Abstract

Motzer, R. J.; Choueiri, T. K.; McDermott, D. F.; Powles, T.; Yao, J.; Ammar, R.; Papillon-Cavanagh, S.; Saggi, S. S.; McHenry, B. M.; Ross-Macdonald, P.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Sarrio, R. G.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC)

Meeting Abstract

Lee, C. H.; Wan, Y.; Smith, A. D.; Xie, R.; Motzer, R. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Immune infiltration and angiogenesis as markers of outcome in the post-nephrectomy setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)

Meeting Abstract

Hakimi, A. A.; Voss, M. H.; Kuo, F.; Silagy, A. W.; Marker, M.; Reising, A.; Millholland, J.; Chan, T. A. T.; Russo, P.; Motzer, R. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial

Meeting Abstract

Ficial, M.; Jegede, O.; Sant'Angelo, M.; Moreno, S.; Braun, D. A.; Wind-Rotolo, M.; Pignon, J. C.; Catalano, P. J.; Sun, M. X. N.; Van Allen, E. M.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)

Meeting Abstract

Choueiri, T. K.; Kluger, H. M.; George, S.; Tykodi, S. S.; Kuzel, T. M.; Perets, R.; Nair, S.; Procopio, G.; Carducci, M. A.; Castonguay, V.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101

Meeting Abstract

Bilen, M. A.; Rini, B. I.; Motzer, R. J.; Larkin, J. M. G.; Haanen, J. B. A. G.; Albiges, L.; Pagliaro, L. C.; Voog, E.; Lam, E. T.; Kislov, N.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

Meeting Abstract

Choueiri, T. K.; Powles, T.; Burotto, M.; Bourlon, M. T.; Zurawski, B.; Oyervides Juárez, V. M.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Girones Sarrio, R.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save